Skip to main content
Top
Published in: Dermatology and Therapy 3/2023

Open Access 02-02-2023 | Lymphoma | Brief Report

Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma

Authors: Erin Boh, Drew Kuraitis, Abby Jacobson, Martha Sikes

Published in: Dermatology and Therapy | Issue 3/2023

Login to get access

Abstract

Introduction

Cutaneous T-cell lymphoma (CTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas characterized by various clinical, molecular, and histopathologic features of the skin. Variants of CTCL share many clinical features with common inflammatory skin diseases such as atopic dermatitis and psoriasis, making accurate and early diagnosis challenging in clinical settings. Inappropriate treatment or a delay in diagnosis can lead to increased morbidity and mortality. Here, we report findings from an online survey that investigated dermatology community practice, knowledge, and education surrounding CTCL.

Methods

An electronic survey of ten questions was developed and approved by physician experts in CTCL to assess experiences in diagnosing and treating CTCL among healthcare providers (HCPs). The survey was deployed to 10,600 US dermatology HCPs, including medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (NPs), and physician assistants (PAs) and excluding HCPs associated with CTCL centers of excellence.

Results

Among 44 HCPs who responded and were eligible for inclusion, 82% had diagnosed between one and ten CTCL cases in the last 5 years. Most respondents (91%) reported that they include CTCL in their differential diagnoses after patients do not respond to treatment of more common conditions. Patients with CTCL were frequently diagnosed with other inflammatory dermatoses—most commonly dermatitis and psoriasis—before a CTCL diagnosis, and many were treated with ineffective therapies for years. The most common length of time before a CTCL diagnosis was made was between 1 and 3 years, though 16% of HCPs reported that patients were treated for other diseases or skin conditions for ≥ 5 years. Two-thirds of HCPs agreed that further education surrounding CTCL is needed.

Conclusions

Given the infrequency of CTCL and its similar presentation to other common dermatologic conditions, increased education of CTCL is needed in the dermatology community to improve patient outcomes.
Literature
1.
go back to reference Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143(7):854–9.CrossRefPubMed Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143(7):854–9.CrossRefPubMed
2.
go back to reference Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192(4):683–96.CrossRefPubMed Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192(4):683–96.CrossRefPubMed
3.
go back to reference Durgin JS, Weiner DM, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: pathways and targets for immune restoration and tumor eradication. J Am Acad Dermatol. 2021;84(3):587–95.CrossRefPubMed Durgin JS, Weiner DM, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: pathways and targets for immune restoration and tumor eradication. J Am Acad Dermatol. 2021;84(3):587–95.CrossRefPubMed
4.
go back to reference Garcia-Diaz N, Piris MA, Ortiz-Romero PL, Vaque JP. Mycosis fungoides and Sezary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers (Basel). 2021;13(8):1931.CrossRefPubMed Garcia-Diaz N, Piris MA, Ortiz-Romero PL, Vaque JP. Mycosis fungoides and Sezary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers (Basel). 2021;13(8):1931.CrossRefPubMed
5.
go back to reference Rakowska A, Jasinska M, Sikora M, et al. Cutaneous T-cell lymphoma in erythrodermic cases may be suspected on the basis of scalp examination with dermoscopy. Sci Rep. 2021;11(1):282.CrossRefPubMedPubMedCentral Rakowska A, Jasinska M, Sikora M, et al. Cutaneous T-cell lymphoma in erythrodermic cases may be suspected on the basis of scalp examination with dermoscopy. Sci Rep. 2021;11(1):282.CrossRefPubMedPubMedCentral
6.
go back to reference Jothishankar B, Venkataraman G, Goldberg RC, Abdulla F. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary syndrome (MF/SS). Ann Diagn Pathol. 2019;43: 151404.CrossRefPubMed Jothishankar B, Venkataraman G, Goldberg RC, Abdulla F. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary syndrome (MF/SS). Ann Diagn Pathol. 2019;43: 151404.CrossRefPubMed
7.
go back to reference Nikolaou V, Papadavid E, Economidi A, et al. Mycosis fungoides in the era of antitumour necrosis factor-alpha treatments. Br J Dermatol. 2015;173(2):590–3.CrossRefPubMed Nikolaou V, Papadavid E, Economidi A, et al. Mycosis fungoides in the era of antitumour necrosis factor-alpha treatments. Br J Dermatol. 2015;173(2):590–3.CrossRefPubMed
8.
go back to reference Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011;64(1):1–6.CrossRefPubMed Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011;64(1):1–6.CrossRefPubMed
9.
go back to reference Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man.” Clin Dermatol. 2005;23(2):206–17.CrossRefPubMed Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man.” Clin Dermatol. 2005;23(2):206–17.CrossRefPubMed
10.
go back to reference Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol. 2010;22(6):821–6.CrossRefPubMed Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol. 2010;22(6):821–6.CrossRefPubMed
11.
12.
go back to reference Hughes CF, Newland K, McCormack C, Lade S, Prince HM. Mycosis fungoides and Sezary syndrome: current challenges in assessment, management and prognostic markers. Australas J Dermatol. 2016;57(3):182–91.CrossRefPubMed Hughes CF, Newland K, McCormack C, Lade S, Prince HM. Mycosis fungoides and Sezary syndrome: current challenges in assessment, management and prognostic markers. Australas J Dermatol. 2016;57(3):182–91.CrossRefPubMed
13.
go back to reference Brunner PM, Jonak C, Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res. 2020;9:331.CrossRef Brunner PM, Jonak C, Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res. 2020;9:331.CrossRef
14.
go back to reference Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14.CrossRefPubMedPubMedCentral Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14.CrossRefPubMedPubMedCentral
15.
go back to reference Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016;5:1882.CrossRef Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016;5:1882.CrossRef
16.
go back to reference Meyer N, Paul C, Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol. 2010;90(1):12–7.CrossRefPubMed Meyer N, Paul C, Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol. 2010;90(1):12–7.CrossRefPubMed
17.
go back to reference Elrod JK, Fortenberry JL Jr. Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017;17(Suppl 1):425.CrossRefPubMedPubMedCentral Elrod JK, Fortenberry JL Jr. Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017;17(Suppl 1):425.CrossRefPubMedPubMedCentral
18.
go back to reference Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S3-16.CrossRefPubMed Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S3-16.CrossRefPubMed
19.
go back to reference Martinez-Escala ME, Posligua AL, Wickless H, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.CrossRefPubMedPubMedCentral Martinez-Escala ME, Posligua AL, Wickless H, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.CrossRefPubMedPubMedCentral
21.
go back to reference Hollins LC, Wirth P, Fulchiero GJ Jr, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8–11.CrossRefPubMed Hollins LC, Wirth P, Fulchiero GJ Jr, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8–11.CrossRefPubMed
22.
go back to reference Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–9.CrossRefPubMedPubMedCentral Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–9.CrossRefPubMedPubMedCentral
23.
go back to reference Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf. 2021;20(9):997–1004.CrossRefPubMed Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf. 2021;20(9):997–1004.CrossRefPubMed
Metadata
Title
Healthcare Provider Experience in Diagnosing and Treating Cutaneous T-Cell Lymphoma
Authors
Erin Boh
Drew Kuraitis
Abby Jacobson
Martha Sikes
Publication date
02-02-2023
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 3/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-00895-2

Other articles of this Issue 3/2023

Dermatology and Therapy 3/2023 Go to the issue